Ian Nessler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ian Nessler has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Greg Michael Thurber
Department of Chemical Engineering, University of Michigan
31 shared publications - Anna Kopp
Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan
25 shared publications - Baron Rubahamya
Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
25 shared publications - Jennifer Donnell
Gilead Sciences, Inc., Morris Plains, New Jersey
25 shared publications - Nalini Sathyanarayan
Gilead Sciences, Inc., Morris Plains, New Jersey
25 shared publications - Scott Hofsess
Gilead Sciences, Inc., Morris Plains, New Jersey
25 shared publications
Latest Publications
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
HiSep XAb-SN-38. HPLC detection at 360 nm, SN-38 absorbance region, with 98.7% associated with the peak corresponding to the antibody. Peak at 8.123 mm is due to unremoved SN-38.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
HiSep XAb-SN-38. HPLC detection at 360 nm, SN-38 absorbance region, with 98.7% associated with the peak corresponding to the antibody. Peak at 8.123 mm is due to unremoved SN-38.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S9 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Quantifying CEACAM6 expression on LS174T cells. Human Fc binding beads (Bangs Laboratories) were incubated with AF488 labelled Tinurilimab biosimilar. Correlation of median fluorescence intensity with number of binding sites per bead was generated and the slope used to calculate the number of CEACAM6 receptors per LS174T cell. Approximately 24,857 antibodies/cell were bound, so CEACAM6 expression was estimated at 49,714 receptors per LS174T cell assuming bivalent binding.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Quantifying CEACAM6 expression on LS174T cells. Human Fc binding beads (Bangs Laboratories) were incubated with AF488 labelled Tinurilimab biosimilar. Correlation of median fluorescence intensity with number of binding sites per bead was generated and the slope used to calculate the number of CEACAM6 receptors per LS174T cell. Approximately 24,857 antibodies/cell were bound, so CEACAM6 expression was estimated at 49,714 receptors per LS174T cell assuming bivalent binding.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
HiSep XAb-SN-38. HPLC detection at 360 nm, SN-38 absorbance region, with 98.7% associated with the peak corresponding to the antibody. Peak at 8.123 mm is due to unremoved SN-38.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
HiSep XAb-SN-38. HPLC detection at 360 nm, SN-38 absorbance region, with 98.7% associated with the peak corresponding to the antibody. Peak at 8.123 mm is due to unremoved SN-38.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
In vitro toxicity curves. LS174T cells were seeded in 96 well plates and then incubated with a serial dilution of either LG or XAb-SN-38 for 6 days with media replacement every 24 hours. The toxicity curves are presented in either protein (A) or payload (B) incubation concentration. Although XAb-SN-38 provided more efficacy in vivo, the two ADCs resulted in similar in vitro potency.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
In vitro toxicity curves. LS174T cells were seeded in 96 well plates and then incubated with a serial dilution of either LG or XAb-SN-38 for 6 days with media replacement every 24 hours. The toxicity curves are presented in either protein (A) or payload (B) incubation concentration. Although XAb-SN-38 provided more efficacy in vivo, the two ADCs resulted in similar in vitro potency.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
In vitro toxicity curves. LS174T cells were seeded in 96 well plates and then incubated with a serial dilution of either LG or XAb-SN-38 for 6 days with media replacement every 24 hours. The toxicity curves are presented in either protein (A) or payload (B) incubation concentration. Although XAb-SN-38 provided more efficacy in vivo, the two ADCs resulted in similar in vitro potency.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
In vitro toxicity curves. LS174T cells were seeded in 96 well plates and then incubated with a serial dilution of either LG or XAb-SN-38 for 6 days with media replacement every 24 hours. The toxicity curves are presented in either protein (A) or payload (B) incubation concentration. Although XAb-SN-38 provided more efficacy in vivo, the two ADCs resulted in similar in vitro potency.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Binding of T84.66 on LS174T cells pre-incubated in a saturating antibody solution. While the binding of fluorescent dye labelled T84.66 is blocked on LS174T cells pre-incubated with unlabeled T84.66, pre-incubation with hMN-14 does not block the binding of labelled T84.66.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Binding of T84.66 on LS174T cells pre-incubated in a saturating antibody solution. While the binding of fluorescent dye labelled T84.66 is blocked on LS174T cells pre-incubated with unlabeled T84.66, pre-incubation with hMN-14 does not block the binding of labelled T84.66.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
SE-HPLC Plot at 280nm for XAb-SN-38. XAb-SN-38 was retained for ~7 minutes similar to the unconjugated ADC.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
SE-HPLC Plot at 280nm for XAb-SN-38. XAb-SN-38 was retained for ~7 minutes similar to the unconjugated ADC.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Binding of T84.66 on LS174T cells pre-incubated in a saturating antibody solution. While the binding of fluorescent dye labelled T84.66 is blocked on LS174T cells pre-incubated with unlabeled T84.66, pre-incubation with hMN-14 does not block the binding of labelled T84.66.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Binding of T84.66 on LS174T cells pre-incubated in a saturating antibody solution. While the binding of fluorescent dye labelled T84.66 is blocked on LS174T cells pre-incubated with unlabeled T84.66, pre-incubation with hMN-14 does not block the binding of labelled T84.66.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
SE-HPLC Plot CEA-IgG. Size-exclusion HPLC (SE-HPLC) of CEA IgG, M85151a (XAb in our description), product #l0-C10C, from Fitzgerald Industries International. HPLC detection at 280 nm, the antibody absorbance region.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
SE-HPLC Plot CEA-IgG. Size-exclusion HPLC (SE-HPLC) of CEA IgG, M85151a (XAb in our description), product #l0-C10C, from Fitzgerald Industries International. HPLC detection at 280 nm, the antibody absorbance region.